NEW YORK, NY, April 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - Nascent Biotech, Inc. (OTCQB: NBIO) (the `Company`), a biotechnology company developing proprietary human Monoclonal Antibodies (mAbs) and immunotherapy for treatment of cancer, was recently featured in an article by leading publisher, SmallCapsDaily. The focus of the SmallCapsDaily feature was Nascent Biotech´s development of a drug therapy, with indications for use against pathogens, like the SARS-CoV-2 virus, which has spread across the globe, resulting in a...
|
